全文获取类型
| 收费全文 | 4043篇 |
| 免费 | 575篇 |
| 国内免费 | 84篇 |
学科分类
| 医药卫生 | 4702篇 |
出版年
| 2023年 | 122篇 |
| 2021年 | 47篇 |
| 2020年 | 67篇 |
| 2019年 | 46篇 |
| 2018年 | 127篇 |
| 2017年 | 141篇 |
| 2016年 | 139篇 |
| 2015年 | 111篇 |
| 2014年 | 170篇 |
| 2013年 | 188篇 |
| 2012年 | 123篇 |
| 2011年 | 121篇 |
| 2010年 | 156篇 |
| 2009年 | 215篇 |
| 2008年 | 130篇 |
| 2007年 | 133篇 |
| 2006年 | 119篇 |
| 2005年 | 108篇 |
| 2004年 | 88篇 |
| 2003年 | 102篇 |
| 2002年 | 86篇 |
| 2001年 | 127篇 |
| 2000年 | 83篇 |
| 1999年 | 106篇 |
| 1998年 | 146篇 |
| 1997年 | 133篇 |
| 1996年 | 116篇 |
| 1995年 | 102篇 |
| 1994年 | 94篇 |
| 1993年 | 76篇 |
| 1992年 | 92篇 |
| 1991年 | 71篇 |
| 1990年 | 91篇 |
| 1989年 | 136篇 |
| 1988年 | 110篇 |
| 1987年 | 61篇 |
| 1986年 | 72篇 |
| 1985年 | 80篇 |
| 1984年 | 51篇 |
| 1983年 | 43篇 |
| 1982年 | 42篇 |
| 1981年 | 31篇 |
| 1980年 | 47篇 |
| 1979年 | 26篇 |
| 1978年 | 28篇 |
| 1977年 | 25篇 |
| 1976年 | 24篇 |
| 1975年 | 26篇 |
| 1974年 | 15篇 |
| 1973年 | 19篇 |
排序方式： 共有4702条查询结果，搜索用时 46 毫秒
1.
Nurse perceptions of the Nursing Delirium Screening Scale in two palliative care inpatient units: a focus group study 
下载免费PDF全文
下载免费PDF全文 2.
3.
A. Cattapan K. Browne D.M. Halperin A. Di Castri P. Fullsack J. Graham J.M. Langley B.A. Taylor S.A. McNeil S.A. Halperin 《Vaccine》2019,37(2):289-295
Introduction/Hypothesis
Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014–2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.Methods
An online survey which included participants’ prior experience with clinical trials, motivations to participate (including financial incentives), and demographic information was developed to examine the motivations of healthy participants in two phase 1 clinical vaccine trials conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia. Participants were invited via email to complete the online survey. Readability and clarity were assessed through pilot testing.Results
A total of 49 (55.7%) of 88 participants of the two studies completed the survey (22 [55%] of 40 participants from the Ebola vaccine study and 27 [56.3%] of 48 from the adjuvanted influenza vaccine study). Motivations that were most frequently ranked among participants' top three in both trials were (1) wanting to contribute to the health of others, (2) wanting to participate in something important, (3) wanting to contribute to the advancement of science, and (4) wanting to receive an incentive such as money or a tablet.Conclusions/Recommendations
Although media attention and financial compensation were more often cited by Ebola vaccine trial participants as a reason to participate, both altruistic and self-interested factors were important motivations for participants in their decision to participate in a phase 1 vaccine clinical trial. 相似文献4.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献5.
Evaluation of training nurses to perform semi‐automated three‐dimensional left ventricular ejection fraction using a customised workstation‐based training protocol 下载免费PDF全文
下载免费PDF全文 6.
Jessica Roberts MBBS Jason Powell MBBS MClinRes PhD MRCS Jacob Begbie MBBS MRes Gerard Siou MBBS MD FRCS Claire McLarnon MBBS MSc FRCS Andrew Welch MBBS FRCS Michael McKean MBChB MD FRCPCH Mathew Thomas MBChB MRCPCH PhD Anne-Marie Ebdon MBBS MRCPCH FRACP Samantha Moss MBBS MRCPCH MD Rachel S. Agbeko MSc MD PhD FRCPCH FFICM Jonathan H. Smith MBChB MRCP FRCA Malcolm Brodlie MB ChB PhD MRCPCH Christopher O'Brien MBBS FRCPCH Steven Powell MBBS MSc FRCS 《The Laryngoscope》2020,130(5):E375-E380
7.
8.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
9.
10.
